公开(公告)号：US20240309381A1

公开(公告)日：2024-09-19

申请号：US18608561

申请日：2024-03-18

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Tara Young ,  Christopher Daly ,  Gavin Thurston

IPC: C12N15/113 ,  A61K45/06 ,  C12N9/22

CPC classification number: C12N15/113 ,  A61K45/06 ,  C12N9/22 ,  C12N2310/11 ,  C12N2310/141 ,  C12N2310/531

Abstract: Provided herein are methods and compositions related to the treatment or prevention of cancer (e.g., by targeting a tumor in a subject with cancer) by administering to a subject an agent that inhibits autophagy. In certain aspects, provided herein are methods of compositions related to methods of sensitizing cancer cells to tumor necrosis factor-alpha (TNF-α) mediated killing by contacting the cells or administering the agent that inhibits autophagy.

公开(公告)号：US20240309316A1

公开(公告)日：2024-09-19

申请号：US18672979

申请日：2024-05-23

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Amy S. Johnson ,  Meghan E. Casey ,  Shadia Oshodi ,  Shawn Lawrence

IPC: C12N5/00 ,  C12N15/79

CPC classification number: C12N5/0018 ,  C12N15/79 ,  C12N2500/33 ,  C12N2500/74 ,  C12N2500/80

Abstract: The specification describes a composition comprising an improved eukaryotic cell culture medium, which can be used for the production of a protein of interest. TaXULne can be added to the serum-free media or chemically-defined media to increase the production of a protein of interest. Methods for recombinantly expressing high levels of protein using the media compositions are included.

公开(公告)号：US20240309064A1

公开(公告)日：2024-09-19

申请号：US18637124

申请日：2024-04-16

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Shunhai Wang ,  Ning Li ,  Hunter Chen ,  Amardeep Singh Bhupender Bhalla ,  Shawn M. Lawrence ,  Amy S. Johnson ,  Meghan Casey ,  Jaimie Grapel

IPC: C07K14/71 ,  A61K38/18 ,  C07K1/113 ,  C07K1/16 ,  C07K1/18 ,  C07K1/22 ,  C07K1/36 ,  C07K16/22 ,  C07K16/28 ,  C12N5/00 ,  C12N15/66 ,  C12P21/02 ,  C12P21/06 ,  G01N30/02 ,  G01N30/80

CPC classification number: C07K14/71 ,  A61K38/1866 ,  C07K1/113 ,  C07K1/16 ,  C07K1/18 ,  C07K1/22 ,  C07K1/36 ,  C07K16/22 ,  C07K16/283 ,  C12N5/0018 ,  C12N5/0031 ,  C12N15/66 ,  C12P21/02 ,  C12P21/06 ,  G01N30/80 ,  C07K2317/622 ,  C07K2319/30 ,  C07K2319/33 ,  C12N2800/10 ,  G01N2030/027

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

公开(公告)号：USD1042107S1

公开(公告)日：2024-09-17

申请号：US29851361

申请日：2022-08-26

Applicant: Regeneron Pharmaceuticals, Inc.

Designer： Andrew Cook ,  Victor Bradford ,  Jason Smith ,  Sibgat Ulla

Abstract: FIG. 1 is a bottom, rear, right perspective view of packaging showing our new design;
FIG. 2 is a bottom, rear, left perspective view thereof;
FIG. 3 is a rear elevation view thereof;
FIG. 4 is a front elevation view thereof;
FIG. 5 is a left side view thereof;
FIG. 6 is a right side view thereof;
FIG. 7 is a bottom plan view thereof; and,
FIG. 8 is a top view thereof.
The broken lines of even length shown in the drawings illustrate portions of the packaging that form no part of the claimed design.

公开(公告)号：US12091460B2

公开(公告)日：2024-09-17

申请号：US16906634

申请日：2020-06-19

Applicant: REGENERON PHARMACEUTICALS, INC.

Inventor： Jessica R. Kirshner ,  Alison Crawford ,  Danica Chiu

IPC: C07K16/46 ,  A61B6/00 ,  A61B6/03 ,  A61K51/10 ,  C07K16/28 ,  C07K16/30 ,  A61K39/00

CPC classification number: C07K16/2809 ,  A61B6/037 ,  A61B6/481 ,  A61K51/1042 ,  C07K16/2878 ,  C07K16/3092 ,  A61K2039/507 ,  C07K2317/31 ,  C07K2317/75

Abstract: Provided herein are method of treating cancer using bispecific antigen-binding molecules that bind to Mucin 16 (MUC16) and CD3. According to certain embodiments, the antibodies useful herein bind human MUC16 with high affinity and bind CD3 to induce human T cell proliferation. According to certain embodiments, bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human MUC16 are particularly useful herein. In certain embodiments, the bispecific antigen-binding molecules in combination with an anti-4-1BB agonist are capable of inhibiting the growth of tumors expressing MUC16, for example, ovarian tumors. The bispecific antigen-binding molecules in combination with an anti-4-1BB agonist are useful for the treatment of diseases and disorders in which an upregulated or induced targeted immune response is desired and/or therapeutically beneficial, for example, in the treatment of various cancers.

公开(公告)号：US12090201B2

公开(公告)日：2024-09-17

申请号：US16985708

申请日：2020-08-05

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Ashish Bansal ,  Neil Graham ,  Paola Mina-Osorio ,  John Davis ,  Mohamed Kamal

IPC: A61K39/395 ,  A61P17/00 ,  A61K39/00 ,  A61K45/06 ,  C07K16/28

CPC classification number: A61K39/3955 ,  A61P17/00 ,  A61K2039/505 ,  A61K2039/545 ,  A61K45/06 ,  C07K16/2866 ,  C07K2317/21 ,  C07K2317/56 ,  C07K2317/76

Abstract: Methods for treating moderate-to-severe or severe atopic dermatitis in a pediatric subject are provided. In one aspect, the methods comprise administering to the subject one or more doses of an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof.

公开(公告)号：US12090193B2

公开(公告)日：2024-09-17

申请号：US18457482

申请日：2023-08-29

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Yang Wei ,  Haruka Okamoto ,  Jesper Gromada ,  Samuel Davis ,  Andrew J. Murphy

IPC: A61K38/26 ,  A61K31/155 ,  A61K31/5415 ,  A61K38/00 ,  A61P3/04 ,  A61P3/10 ,  C07K14/605 ,  C07K16/08 ,  C07K16/28 ,  C12N15/62

CPC classification number: A61K38/26 ,  A61K31/155 ,  A61K31/5415 ,  A61P3/04 ,  A61P3/10 ,  C07K14/605 ,  C07K16/082 ,  C07K16/2869 ,  C12N15/62 ,  A61K38/00 ,  C07K2319/00

Abstract: The present invention provides modified glucagon-like peptide 1 (GLP1) polypeptides, fusion proteins comprising modified GLP1 polypeptides, and methods of use thereof. In various embodiments of the invention, the fusion proteins are GLP1 receptor agonists that comprise a modified GLP1 fused to a stabilizing domain. In some embodiments, the fusion proteins comprising modified GLP1 are useful for treating or ameliorating a symptom or indication of a disorder such as obesity and diabetes.

公开(公告)号：US12089575B2

公开(公告)日：2024-09-17

申请号：US17110868

申请日：2020-12-03

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Elena Burova ,  Yajun Tang ,  Ka-Man Venus Lai ,  Andrew J. Murphy

IPC: A01K67/027 ,  A01K67/0278 ,  A61K49/00 ,  C07K14/705 ,  C07K16/30 ,  A61K39/00

CPC classification number: A01K67/0278 ,  A61K49/0008 ,  C07K14/70596 ,  C07K16/30 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/02 ,  A01K2267/03 ,  A01K2267/0331 ,  A61K2039/505

Abstract: Non-human animals, methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of a Cluster of Differentiation 274 (CD274) gene. Such non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous CD274 gene so that said non-human animals express a Programmed cell death ligand 1 (PD-L) polypeptide that includes a human portion and an endogenous portion (e.g., a non-human portion).

公开(公告)号：US20240294606A1

公开(公告)日：2024-09-05

申请号：US18638362

申请日：2024-04-17

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Shunhai Wang ,  Ning Li ,  Hunter Chen ,  Amardeep Singh Bhupender Bhalla ,  Shawn M. Lawrence ,  Amy Johnson ,  Meghan Casey ,  Jaimie Grapel

IPC: C07K14/71 ,  A61K38/18 ,  C07K1/113 ,  C07K1/16 ,  C07K1/18 ,  C07K1/22 ,  C07K1/36 ,  C07K16/22 ,  C07K16/28 ,  C12N5/00 ,  C12N15/66 ,  C12P21/02 ,  C12P21/06 ,  G01N30/02 ,  G01N30/80

CPC classification number: C07K14/71 ,  A61K38/1866 ,  C07K1/113 ,  C07K1/16 ,  C07K1/18 ,  C07K1/22 ,  C07K1/36 ,  C07K16/22 ,  C07K16/283 ,  C12N5/0018 ,  C12N5/0031 ,  C12N15/66 ,  C12P21/02 ,  C12P21/06 ,  G01N30/80 ,  C07K2317/622 ,  C07K2319/30 ,  C07K2319/33 ,  C12N2800/10 ,  G01N2030/027

Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.

公开(公告)号：US12077782B2

公开(公告)日：2024-09-03

申请号：US17317602

申请日：2021-05-11

Applicant: Regeneron Pharmaceuticals, Inc.

Inventor： Jena Daya ,  Valerie Ann Cusick ,  John Mattila

IPC: C12N7/00 ,  C07K1/14 ,  C07K16/10

CPC classification number: C12N7/00 ,  C07K1/14 ,  C07K16/1036 ,  C12N2740/13063

Abstract: Methods for viral clearance using low pH hold based on a statistical design of experiment are provided. Several factors are evaluated to characterize the impacts of a low pH hold step for virus inactivation, including the factors of pH conditions, conductivity conditions, protein type, temperature, acid titrant, spike timing, and post-spike filtration. In addition to the effect of pH on virus inactivation, an increase in ionic strength through manipulating the conductivity can be a key component that influences virus inactivation kinetics.